Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations
Cardiac amyloidosis is a progressive infiltrative disease and an important cause of atrial arrhythmias, stroke and heart failure. Abnormal amyloid fibril deposition throughout the heart leads to a host of clinical manifestations and complications. Although atrial abnormalities are typically regarded as a consequence of ventricular diastolic dysfunction or atrial arrhythmias, there is emerging evidence that primary defects of atrial structure and function may be present. An atrial cardiomyopathy may be a sign of early cardiac disease, and an unrecognised independent marker of worse prognosis.This review summarizes current evidence specifically for atrial cardiomyopathy in cardiac amyloidosis, with a focus on imaging and clinical outcomes.
Authors
- N. Bart (ORCID: https://orcid.org/0000-0002-3546-0758)
- Vanathi Sivasubramaniam
- Antonia Carroll (ORCID: https://orcid.org/0000-0002-1738-9580)
- Paul Geenty (ORCID: https://orcid.org/0000-0002-6737-6040)
- Liza Thomas (ORCID: https://orcid.org/0000-0001-6045-7780)
- Georgia J. B. McCaughan (ORCID: https://orcid.org/0000-0002-4838-9022)
- Eleanor Rye (ORCID: https://orcid.org/0000-0002-8235-785X)
- Diane Fatkin (ORCID: https://orcid.org/0000-0002-9010-9856)
- Natasha Gorrie
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Victor Chang Cardiac Research Institute (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Cooperative Trials Group for Neuro-Oncology (AU)
Publication Details
- Journal
- npj Cardiovascular Health
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1038/s44325-025-00043-z
- Citations
- 6
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.84